title: A wish list for molecular tests.
abstract: Companion diagnostics improve health outcomes, say developers, who are willing to work with payers to develop medical policies for coverage. Payers and clinicians want more evidence of long-term benefit. The FDA, meanwhile, is jostling for regulatory control. How long will patients have to wait? Part 2 of 2.
authors.forename: Bob
authors.initials: B
authors.lastname: Carlson